Breaking News Instant updates and real-time market news.

FOLD

Amicus

$14.56

0.37 (2.61%)

07:05
08/07/18
08/07
07:05
08/07/18
07:05

Amicus reports Q2 EPS (33c), consensus (33c)

Reports Q2 revenue $21.3M, consensus $19.16M.

  • 07

    Aug

  • 13

    Aug

  • 12

    Sep

FOLD Amicus
$14.56

0.37 (2.61%)

09/15/17
JPMS
09/15/17
NO CHANGE
Target $15
JPMS
Overweight
JPMorgan continues to see upside in Amicus shares
JPMorgan analyst Anupam Rama says Amicus Therapeutics remains one of his top picks, and that he continues to see upside from current share levels, ahead of the upcoming Pompe data readout. The analyst sees a high probability that the Q3 data update will meet or exceed the efficacy benchmarks, leading to increased probability of success/revenue estimates across Street models. His base case, with a 75% probability of success assumption, still provides for 10%-15% upside from current share levels. His "homerun scenario," which is maintaining the 6MWD benefit shown in Q2 or better, has the stock rallying 35%-40%.
10/04/17
BOFA
10/04/17
NO CHANGE
Target $20
BOFA
Buy
Amicus price target raised to $20 from $15 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised Amicus' price target to $20 from $15 saying the Phase 1/2 trial results of ATB200/AT2221 in Pompe disease were impressive. The analyst thinks the strong data justifies progression into pivotal trials and may result in an accelerated approval path. Ahmad rates Amicus a Buy.
04/11/18
JPMS
04/11/18
NO CHANGE
JPMS
Overweight
Amicus risk/reward favorable into regulatory update, says JPMorgan
JPMorgan analyst Anupam Rama notes that a regulatory update for Amicus Therapeutics' Pompe program is expected in Q2. The analyst continues to like the reward/risk profile of the shares going into the update. An accelerated approval path forward is "very much on the table," based on the strength of the Phase 1/2 data, Rama tells investors in a research note. He sees "more win scenarios than lose." The analyst believes Amicus shares can rally 30%-50% should an accelerated approval path forward emerge. Rama keeps an Overweight rating on Amicus with a $19 price target.
05/08/18
JPMS
05/08/18
NO CHANGE
JPMS
Amicus lower on Pompe program commentary, says JPMorgan
JPMorgan analyst Anupam Rama attributes today's post-earnings weakness in shares of Amicus Therapeutics to "conservative commentary" on the call related to the Pompe program. The analyst, however, does not believe that the regulatory scenarios he outlined last month for the program have fundamentally changed. Nonetheless, Rama thinks commentary on the call, particularly on timing, was perceived as cautious. Amicus shares are down 7.5% to $13.49 in midday trading.

TODAY'S FREE FLY STORIES

PSNL

Personalis

$0.00

(0.00%)

10:59
06/20/19
06/20
10:59
06/20/19
10:59
Syndicate
Personalis indicated to open at $28, IPO priced at $17 »

Personalis (PSNL) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AGCO

Agco

$75.20

0.33 (0.44%)

10:57
06/20/19
06/20
10:57
06/20/19
10:57
Conference/Events
Agco management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

WORK

Slack Technologies

$0.00

(0.00%)

10:54
06/20/19
06/20
10:54
06/20/19
10:54
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies direct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

VanEck Vectors Gold Miners ETF

$24.79

0.82 (3.42%)

10:50
06/20/19
06/20
10:50
06/20/19
10:50
Options
Recent call buyer in Gold Miners ETF hit the mother lode on Fed stance »

Recent call buyer in Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$11.13

-0.39 (-3.39%)

10:45
06/20/19
06/20
10:45
06/20/19
10:45
Options
AMC Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

10:45
06/20/19
06/20
10:45
06/20/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
06/20/19
06/20
10:45
06/20/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

TSN

Tyson Foods

$77.87

0.1 (0.13%)

10:45
06/20/19
06/20
10:45
06/20/19
10:45
Earnings
Tyson Foods sees adjusted EPS growth in 'high single digits' »

In analyst day slides,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AAPL

Apple

$198.90

1.03 (0.52%)

10:44
06/20/19
06/20
10:44
06/20/19
10:44
Hot Stocks
Apple, in letter to Lighthizer, urges U.S. not to impose additional tariffs »

Apple said in a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.16

0.11 (0.58%)

, EADSY

Airbus

$0.00

(0.00%)

10:43
06/20/19
06/20
10:43
06/20/19
10:43
Periodicals
JetBlue to order 13 A321XLR aircraft from Airbus, Reuters says »

JetBlue (JBLU) will order…

JBLU

JetBlue

$19.16

0.11 (0.58%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCEL

Atreca

$0.00

(0.00%)

10:40
06/20/19
06/20
10:40
06/20/19
10:40
Syndicate
Breaking Syndicate news story on Atreca »

Atreca opens at $19.90,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

DPUKY

Domino's Pizza Group

$0.00

(0.00%)

10:38
06/20/19
06/20
10:38
06/20/19
10:38
Periodicals
Domino's Pizza Group in talks to replace CEO, Sky News reports »

Domino's Pizza Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$160.99

-1.56 (-0.96%)

10:35
06/20/19
06/20
10:35
06/20/19
10:35
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIP

ANI Pharmaceuticals

$76.25

1.86 (2.50%)

10:33
06/20/19
06/20
10:33
06/20/19
10:33
Hot Stocks
ANI Pharmaceuticals announces FDA approval for Vancomycin supplement »

ANI Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACRS

Aclaris Therapeutics

$5.25

0.14 (2.74%)

10:31
06/20/19
06/20
10:31
06/20/19
10:31
Hot Stocks
FDA says Aclaris ad makes false or misleading claims about Eskata »

The FDA sent a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
06/20/19
06/20
10:30
06/20/19
10:30
General news
EIA natural gas storage change for week ending June 14 »

Gas inventories 115 Bcf…

10:30
06/20/19
06/20
10:30
06/20/19
10:30
General news
Treasury Action: Treasuries remain richer on the day »

Treasury Action:…

GO

Grocery Outlet

$0.00

(0.00%)

10:28
06/20/19
06/20
10:28
06/20/19
10:28
Syndicate
Grocery Outlet indicated to open at $30, IPO priced at $22 »

Grocery Outlet (GO)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

10:27
06/20/19
06/20
10:27
06/20/19
10:27
General news
Trump tweets 'Iran made a very big mistake' »

President Trump tweeted,…

BCEL

Atreca

$0.00

(0.00%)

10:25
06/20/19
06/20
10:25
06/20/19
10:25
Syndicate
Atreca indicated to open at $20.30, IPO priced at $17.00 »

Atreca (BCEL) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

10:25
06/20/19
06/20
10:25
06/20/19
10:25
Conference/Events
Jefferies technology analysts to hold an analyst/industry conference call »

Analysts, along with Alan…

CVS

CVS Health

$53.97

-0.92 (-1.68%)

10:25
06/20/19
06/20
10:25
06/20/19
10:25
Conference/Events
CVS Health participates in a conference call with Morgan Stanley »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

VSTM

Verastem

$1.72

-0.18 (-9.47%)

10:21
06/20/19
06/20
10:21
06/20/19
10:21
Downgrade
Verastem rating change at BTIG »

Verastem downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$0.00

(0.00%)

10:20
06/20/19
06/20
10:20
06/20/19
10:20
Syndicate
Slack Technologies direct listing indicated to open at $30-$34 per share »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$130.24

2.35 (1.84%)

10:20
06/20/19
06/20
10:20
06/20/19
10:20
Options
Gold ETF option volume 7x normal as spot jumps 2% »

Gold ETF option volume 7x…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.